ERYCETTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ERYCETTE (ERYCETTE).
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. This action is bacteriostatic or bactericidal depending on concentration and organism.
| Metabolism | Erythromycin is metabolized primarily in the liver via demethylation by CYP3A4. It is a substrate and inhibitor of CYP3A4. |
| Excretion | Primarily hepatic metabolism; <5% excreted unchanged in urine; ~20% excreted in feces via bile. |
| Half-life | Approximately 1.5–2 hours; prolonged in hepatic impairment. |
| Protein binding | Erythromycin base: 70–90% bound to serum proteins, primarily alpha-1-acid glycoprotein. |
| Volume of Distribution | Not well defined for topical use; systemic absorption negligible; IV Vd: 0.6–0.9 L/kg indicating extensive tissue distribution. |
| Bioavailability | Topical: minimal systemic absorption (<0.1%); oral base: 35%; estolate: variable (can be higher). |
| Onset of Action | Topical: therapeutic effect seen within 2–3 weeks of regular application. |
| Duration of Action | Sustained antibacterial effect on skin; applied twice daily; no systemic duration applicable. |
| Molecular Weight | 733.93 |
Apply topically twice daily to affected areas.
| Dosage form | SWAB |
| Renal impairment | No dose adjustment required; renal excretion is minimal. |
| Liver impairment | No dose adjustment required; hepatic metabolism is minimal. |
| Pediatric use | Not recommended for children under 12 years of age. |
| Geriatric use | Use with caution; no specific dose adjustment recommended. |
| 1st trimester | Avoid use; erythromycin estolate is associated with maternal hepatotoxicity; topical erythromycin is generally considered low risk but limited data. |
| 2nd trimester | Topical use likely safe; systemic absorption minimal. |
| 3rd trimester | Use if clearly needed; no known fetal risk but avoid prolonged use near term due to theoretical risk of pyloric stenosis. |
Clinical note
Comprehensive clinical and safety monograph for ERYCETTE (ERYCETTE).
| Placental transfer | Minimal to none with topical application; systemic absorption <5%. |
| Breastfeeding | Topical erythromycin is minimally absorbed systemically; unlikely to cause adverse effects in breastfed infants. Avoid application to breast area. |
| Lactation Rating |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to erythromycin or any componentPre-existing liver disease (estolate salt, but ERYCETTE is base form; still contraindicated with hepatic impairment)
| Precautions | May cause QT prolongation and serious cardiac arrhythmias, especially in patients with pre-existing QT prolongation, electrolyte disturbances, or concomitant use of other QT-prolonging drugs, Potential for Clostridioides difficile-associated diarrhea (CDAD), May exacerbate myasthenia gravis, Hepatic dysfunction, including jaundice and hepatitis |
| Food/Dietary | No significant food interactions. Erythromycin topical solution is applied externally and not absorbed systemically in significant amounts; dietary restrictions are not required. |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | Topical erythromycin (ERYCETTE) has minimal systemic absorption; however, based on oral erythromycin use, there is no evidence of teratogenicity in humans. First trimester: No increased risk of major malformations reported. Second and third trimesters: No specific fetal risks identified. Use is generally considered safe during pregnancy. |
| Fetal Monitoring | No specific monitoring required due to minimal systemic exposure. Routine prenatal care is sufficient. |
| Fertility Effects | No known adverse effects on fertility from topical erythromycin. No studies indicate impaired reproductive function. |
| Clinical Pearls | Erycette (erythromycin topical solution) is effective for inflammatory acne due to its anti-inflammatory and antibacterial properties. Avoid contact with eyes, mucous membranes, and broken skin. Use sparingly; overuse may cause skin irritation. Combination with benzoyl peroxide can reduce development of bacterial resistance. |
| Patient Advice | Apply a thin layer to affected areas once or twice daily as directed. · Avoid getting the solution in your eyes, nose, or mouth. · Wash your hands before and after application. · Do not use more than prescribed; it will not work faster and may increase irritation. · Inform your doctor if you develop severe irritation or allergic reaction. · It may take 2-6 weeks to see improvement; continue use as directed even if acne worsens initially. · Keep away from heat or open flame; solution is flammable. |